Related Experiment Video

Updated: Jul 25, 2025

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.7K

Esomeprazole Alleviates Cisplatin Resistance by Inhibiting the AKT/mTOR Pathway in Ovarian Cancer Cells

Jingya Duan1, Zisen Zhang2, Jinfeng Du2

  • 1Department of Gynecology, the Third Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, People's Republic of China.

Oncotargets and Therapy
|June 26, 2023
PubMed
Abstract

Insights

Esomeprazole (ESO) shows anticancer effects on ovarian cancer cells, inhibiting growth and inducing apoptosis. It also enhances cisplatin

Area of Science:

  • Gynecologic Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Ovarian cancer is the leading cause of gynecologic cancer mortality.
  • Limited treatment options and platinum resistance necessitate novel therapeutic strategies.
  • Esomeprazole (ESO) exhibits preclinical and clinical anticancer activities.

Purpose of the Study:

  • To investigate the anticancer effects of esomeprazole (ESO) on ovarian cancer.
  • To elucidate the molecular mechanisms underlying ESO's action in ovarian cancer.
  • To evaluate ESO's potential in overcoming cisplatin resistance.

Main Methods:

  • Cell viability and proliferation assessed by CCK-8 and EdU assays.
  • Cell migration and invasion evaluated using Transwell assays.
  • Apoptosis detected by flow cytometry; protein expression analyzed via Western blotting and immunofluorescence.

Main Results:

  • ESO inhibited ovarian cancer cell viability, proliferation, migration, and invasion in a dose-dependent manner, while inducing apoptosis.
  • ESO modulated key proteins involved in cell cycle, apoptosis, and epithelial-mesenchymal transition (EMT), including downregulation of c-MYC, SKP2, E2F1, N-cadherin, vimentin, MMP2, and PI3K/AKT/mTOR pathway, and upregulation of E-cadherin, caspase3, p53, BAX, and cleaved PARP.
  • Combination therapy with ESO and cisplatin demonstrated synergistic effects on cisplatin-resistant ovarian cancer cells, enhancing DNA damage (γH2A.X) and apoptosis.

Conclusions:

  • Esomeprazole exhibits significant anticancer activities against ovarian cancer.
  • ESO demonstrates synergistic efficacy with cisplatin, offering a promising strategy to improve chemosensitivity and overcome resistance in ovarian cancer.
  • The findings support ESO as a potential therapeutic agent for ovarian cancer, particularly in combination regimens.
Keywords:
AKT/mTOR pathwaycisplatin resistanceesomeprazoleovarian cancersynergistic effect

More Related Videos

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

8.7K
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.6K

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
251
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
208
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.7K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K